Our News on Newswise

MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors

MD Anderson and Refuge have announced a strategic collaboration to advance new cell therapies for treating solid tumors. The agreement pairs Refuge's innovative technologies with the experience and capabilities of MD Anderson's Therapeutics...
17-May-2021 8:00 AM EDT Add to Favorites

Newswise: 194784_Rezvani_K_01.jpg

NK cells with bispecific antibody show activity against lymphoma cells

Cord blood-derived natural killer cells combined with a bispecific antibody displayed potent activity against lymphoma cells in a preclinical study led by MD Anderson researchers.
12-May-2021 1:35 PM EDT Add to Favorites

MD Anderson and Broad Institute launch new translational research platform focused on rare cancers

MD Anderson and the Broad Institute have launched a translational research platform to study rare cancers. The initiative will lead to a first-of-its-kind resource for the scientific community and will help to accelerate new therapies for patients...
11-May-2021 9:00 AM EDT Add to Favorites

Newswise: 189250_Gan_B.jpg

Mitochondrial enzyme found to block cell death pathway points to new cancer treatment strategy

MD Anderson researchers have discovered a new role for the DHODH enzyme in blocking a form of cell death called ferroptosis. Preclinical findings suggest that targeting DHODH could restore cell death and inhibit tumor growth.
11-May-2021 8:00 AM EDT Add to Favorites

Newswise: 149163_Kadara_H.jpg

Single-cell map of early stage lung cancer and normal lung sheds light on tumor development, new therapeutic targets

MD Anderson researchers have developed a first-of-its-kind atlas of early-stage lung cancer and surrounding normal lung tissue. The single-cell map provides a valuable resource to learn about tumor development and find new therapeutic targets.
7-May-2021 12:10 PM EDT Add to Favorites

Newswise: 20191113_Katy_Rezvani_027.jpg

Antiviral T cells safe and effective for treating debilitating complication common after stem cell transplants

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis...
30-Apr-2021 3:25 PM EDT Add to Favorites

MD Anderson advances data collaboration through technology agreement with Syntropy

The University of Texas MD Anderson Cancer Center today announced efforts to advance its capabilities to seamlessly connect basic science, translational and clinical research data for the benefit of patients through a technology collaboration with...
29-Apr-2021 9:00 AM EDT Add to Favorites

MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer

MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
14-Apr-2021 9:00 AM EDT Add to Favorites


See All News

Our Experts on Newswise

Newswise: BenjaminSmith.jpg

Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT

Newswise: Liang_H_Bronto.jpg

Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT

Newswise: ZhiminLu.jpg

MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT

Newswise: Lee_M.jpg

Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT

Newswise: 204929_Chhatwal_Jjpg.jpg

MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

See All Experts

Our YouTube Videos

About

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990 and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Contacts

Clayton Boldt
Program Manager, Public Relations

crboldt@mdanderson.org

713-792-9518

Katrina Burton
Senior Communications Specialist

kburton@mdanderson.org

713-792-8034

Shanley Chien
Program Manager, Public Relations

shchien@mdanderson.org

713-563-4250

Lany Kimmons

rlkimmons@mdanderson.org

713-563-5801

Kelley Murfin

kpmurfin@mdanderson.org

Meagan Raeke

meraeke@mdanderson.org

Allison Schaffer
Senior Communications Specialist

ASchaffer@mdanderson.org

713-745-1357

Twitter

close
0.5273